PAPP-A Biomarker Detection for Oocyte Maturation Timing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting ovulation and assessing oocyte maturation in females are inaccurate and inefficient, impacting the success rate of fertility treatments such as in vitro fertilization (IVF).
Innovation Solution
Detecting pregnancy-associated plasma protein A (PAPP-A) levels in bodily fluids, using antibodies to monitor changes over time, and administering chorionic gonadotropin or luteinizing hormone when PAPP-A levels indicate advanced oocyte maturation, to optimize egg harvesting and fertilization timing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ultrasound, CT-scan, and estimation methods are used to determine ovulation timing and oocyte maturation, then the current protocol can be implemented, but the accuracy and efficiency of predicting ovulation and assessing oocyte maturation are insufficient
Solution Approach 1:
The patent replaces mechanical imaging methods (ultrasound, CT-scan) with a biochemical detection system that measures PAPP-A protein levels in follicular fluid or serum. This substitution uses immunoassay technology to detect and quantify PAPP-A, providing a more accurate and simpler method for assessing oocyte maturation and predicting ovulation timing without requiring complex imaging equipment
Solution Approach 2:
The patent introduces PAPP-A protein as a biochemical intermediary marker that reflects oocyte maturation status. By measuring PAPP-A levels in bodily fluids, the method uses this intermediary substance to indirectly assess follicular development and predict ovulation, replacing direct imaging of the reproductive organs with a simpler blood or fluid test
2Measurement precision
If daily monitoring of PAPP-A levels is performed to accurately assess oocyte maturation changes, then the accuracy of timing ovulation and assessing maturation is improved, but the time and resources required for monitoring increase
Solution Approach 1:
The patent performs daily PAPP-A level measurements during the follicular phase to track maturation progression before ovulation occurs. By monitoring changes over time rather than relying on single-point measurements, the method predicts the optimal timing for hCG administration and egg harvesting, allowing proactive planning of IVF procedures based on the maturation trajectory
Solution Approach 2:
The patent uses serial PAPP-A measurements as feedback to assess the rate and extent of oocyte maturation. By comparing PAPP-A levels across multiple days, clinicians can determine when maturation has reached the optimal point for intervention, adjusting the timing of hCG administration and egg retrieval based on the observed maturation pattern rather than following a fixed schedule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate and efficient method for timing ovulation and assessing oocyte maturation, enhancing the success rate of fertility treatments by correlating PAPP-A levels with follicular maturation and fertilization rates.
Implementation Method 1
the step of detecting the PAPP-A level is performed in an immunoassay using an anti-PAPP-A antibody
Data Source
AI summary
The present invention provides methods and kits for assessing the state of oocyte maturation in a female mammal based on the level of PAPP-A found in the female's bodily fluid sample.